Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration

Obinata, Daisuke; Takada, Shigeo; Takayama, Ken‐ichi; Urano, Tomohiko; Ito, Akiko; Ashikari, Daisaku; Fujiwara, Kyoko; Yamada, Yuta; Murata, Toshiki; Kumagai, Jun; Fujimura, Tetsuya; Ikeda, Kazuhiro; Horie‐Inoue, Kuniko; Homma, Yukio; Takahashi, Satoru; Inoue, Satoshi

doi:10.1016/j.ejca.2016.01.002

Cited by 22 publications

(28 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We transfected cells with siRNA using Lipofectamine RNAi MAX (Thermo Fisher Scientific) according to the manufacture's protocol. We purchased control siRNA and other siRNAs from Sigma Genosys Japan as described . We designed siRNAs targeting OCT1.…”

Section: Methodsmentioning

confidence: 99%

“…The antigen‐antibody complex was visualized with DAB solution (1 mmol/L DAB, 50 mmol/L Tris‐HCl buffer [pH 7.6], and 0.006% H 2 O 2 ). Immunoreactivity (IR) score was calculated by the staining intensity (score 0, none; score 1, weak; score 2, moderate; score 3, strong) of positively stained cells and the proportion of positive cells to total cells (under 200× magnification) (score 0, none; score 1, <1/100; score 2, 1/100 to 1/10; score 3, 1/10 to 1/3; score 4, 1/3 to 2/3; score 5, >2/3) . Immunostained slides were evaluated blind to clinical information by two urological pathologists and specimens were defined as positive when the score was 5 or greater.…”

Section: Methodsmentioning

confidence: 99%

“…We purchased control siRNA and other siRNAs from Sigma Genosys Japan as described. 11 We designed siRNAs targeting OCT1.…”

Section: Small Interfering Rnamentioning

confidence: 99%

“…In recent work, we investigated an OCT1 genome-wide network in a CRPC model cell line, 22Rv1. 11 We then observed that OCT1 binding is greater in CRPC model cells compared with AR-dependent prostate cancer, LNCaP. ANLN was identified as one of the major OCT1-target genes in CRPC, which is highly induced specifically in 22Rv1 cells and facilitates cell cycle progression.…”

mentioning

confidence: 90%

“…In recent work, we investigated an OCT1 genome‐wide network in a CRPC model cell line, 22Rv1 . We then observed that OCT1 binding is greater in CRPC model cells compared with AR‐dependent prostate cancer, LNCaP.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Identification of new octamer transcription factor 1‐target genes upregulated in castration‐resistant prostate cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

Octamer transcription factor 1 (OCT1) is an androgen receptor (AR)‐interacting partner and regulates the expression of target genes in prostate cancer cells. However, the function of OCT1 in castration‐resistant prostate cancer (CRPC) is not fully understood. In the present study, we used 22Rv1 cells as AR‐positive CRPC model cells to analyze the role of OCT1 in CRPC. We showed that OCT1 knockdown suppressed cell proliferation and migration of 22Rv1 cells. Using microarray analysis, we identified four AR and OCT1‐target genes, disks large‐associated protein 5 (DLGAP5), kinesin family member 15 (KIF15), non‐SMC condensin I complex subunit G (NCAPG), and NDC80 kinetochore complex component (NUF2) in 22Rv1 cells. We observed that knockdown of DLGAP5 and NUF2 suppresses growth and migration of 22Rv1 cells. Furthermore, immunohistochemical analysis showed that positive expression of DLGAP5 in prostate cancer specimens is related to poor cancer‐specific survival rates of patients. Notably, enhanced expression of DLGAP5 was observed in CRPC tissues of patients. Thus, our findings suggest that these four genes regulated by the AR/OCT1 complex could have an important role in CRPC progression.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…We purchased control siRNA and other siRNAs from Sigma Genosys Japan as described. 11 We designed siRNAs targeting OCT1.…”

Section: Small Interfering Rnamentioning

confidence: 99%

mentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Identification of new octamer transcription factor 1‐target genes upregulated in castration‐resistant prostate cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques

Handley

Eide

Taylor³

et al. 2016

The Laryngoscopes

View full text Add to dashboard Cite

Objective Peroxisome proliferator-activated receptor γ (PPARγ) agonists have been shown to have anti-proliferative, anti-angiogenic, and pro-apoptotic effects, leading to interest in their use as cancer therapeutics. Pioglitazone, an FDA approved type II diabetes medication and PPARγ agonist, may have a role in adjuvant HNSCC treatment or prevention. Therefore, the purpose of this study was: 1) to treat oral cavity cancer cells with the PPARγ activator, pioglitazone, to analyze gene expression changes and 2) to compare those changes with our pre-existing genomic data for development of hypothesis driven additional basic and clinical studies. Study Design Prospective in vitro Methods We utilized microarray technology, as well as, OCPlus and Ingenuity Pathway Analysis to analyze differential gene expression in tumor and pioglitazone-treated tumor cells on a genome wide level to demonstrate the feasibility of such an approach and determine appropriate sample size for future investigations. Results We found approximately 35 samples are required to adequately power future studies. We next discovered pioglitazone significantly affects iCOS-iCOSL and type II Diabetes Mellitus pathways as a putative anti-cancer mechanism. Conclusions Genome wide analysis is possible for exploration of differential pathway modulation and rapid hypothesis generation. Both inflammation and type II diabetes pathways were significantly altered and therefore might provide unique hypothesis-driven pharmacodynamic parameters for future in vitro or in vivo studies utilizing thiazolidinediones. These techniques could be applied to microarray or other high throughput data from a variety of hypothesis-generating research scenarios in otolaryngology (e.g. middle ear proteomics, sinus microbiome studies, etc.). Level of Evidence NA

show abstract

Radiometric Assay of ABHD2 Activity

Fazio

Criscuolo

Maccarrone

2022

Methods in Molecular Biology

View full text Add to dashboard Cite

Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration

Cited by 22 publications

References 42 publications

Identification of new octamer transcription factor 1‐target genes upregulated in castration‐resistant prostate cancer

Identification of new octamer transcription factor 1‐target genes upregulated in castration‐resistant prostate cancer

PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques

Radiometric Assay of ABHD2 Activity

Contact Info

Product

Resources

About